New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NTE;CTIC;NIHD;IMOS;EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
09:26 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTEXELExelixis' cobimetinib granted first regulatory approval in Switzerland
Subscribe for More Information
August 25, 2015
06:25 EDTNIHDAT&T to rebrand services in Mexico, WSJ reports
Subscribe for More Information
August 24, 2015
08:32 EDTEXELExelixis granted FDA Breakthrough Therapy Designation for cabozantinib
Subscribe for More Information
August 21, 2015
10:29 EDTCTICCTI BioPharma strength attributed to abstract posted on PubMed
Subscribe for More Information
August 17, 2015
06:22 EDTEXELPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use